1. Home
  2. SHIM vs TLSA Comparison

SHIM vs TLSA Comparison

Compare SHIM & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shimmick Corporation

SHIM

Shimmick Corporation

HOLD

Current Price

$4.14

Market Cap

160.8M

Sector

N/A

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.07

Market Cap

145.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SHIM
TLSA
Founded
1990
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
160.8M
145.1M
IPO Year
2023
2017

Fundamental Metrics

Financial Performance
Metric
SHIM
TLSA
Price
$4.14
$1.07
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
86.3K
1.1M
Earning Date
05-14-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
81.95
N/A
EPS
N/A
N/A
Revenue
$492,844,000.00
N/A
Revenue This Year
$13.99
N/A
Revenue Next Year
$6.94
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.63
N/A
52 Week Low
$1.95
$0.87
52 Week High
$6.76
$2.35

Technical Indicators

Market Signals
Indicator
SHIM
TLSA
Relative Strength Index (RSI) 54.86 53.57
Support Level $4.05 $0.90
Resistance Level $4.09 $1.17
Average True Range (ATR) 0.28 0.09
MACD 0.01 0.02
Stochastic Oscillator 41.95 56.84

Price Performance

Historical Comparison
SHIM
TLSA

About SHIM Shimmick Corporation

Shimmick Corp is engaged in delivering turnkey infrastructure solutions that strengthen critical markets across water, energy, climate resiliency, and sustainable transportation. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains critical infrastructure, including mass transit, bridges, and military infrastructure. The company has one operating and reportable segment: infrastructure solutions. All of its revenue is derived from the United States.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Share on Social Networks: